伊布替尼真实世界使用模式与安全性研究
47.1%患者发生至少1次伊布替尼相关严重ADR(SADR),12个月累积概率54.3%。年龄≥80岁和慢性淋巴细胞白血病(CLL)与SADR风险升高显著相关。
要点
- 伊布替尼相关SADR 12个月累积发生概率达54.3%。
- 年龄≥80岁与CLL是SADR发生的独立危险因素。
- 42.1%患者首年永久停药,主要因疾病进展或ADR。
核心结论
- 伊布替尼治疗首年内相关SADR累积发生率较高。
- 年龄≥80岁或CLL患者需特别关注SADR风险。
研究设计与样本
- 从医疗记录收集患者特征、伊布替尼使用和ADR资料。
- 采用Kaplan-Meier法估计SADR发生概率(95%CI),Cox比例风险模型分析相关因素。
主要发现
- 中位年龄70.3岁(四分位距64.7-75.6),男女比2.9。
- 47.1%患者因CLL处方伊布替尼。
- 42.1%患者在首年永久停药,主要原因为疾病进展(51.2%)或ADR(32.6%)。
- 47.1%患者发生至少1次伊布替尼相关SADR,血液、感染和血管疾病最常见。
- SADR累积概率3个月35.1%(95%CI 26.3-45.7%),6个月44.8%(35.2%-55.8%),12个月54.3%(44.0%-65.2%)。
临床怎么用
- 对年龄≥80岁或CLL患者启动伊布替尼治疗时,应加强SADR监测与随访。
- 首年尤其前6个月需关注血液学、感染和血管类SADR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To provide real-life data on patterns of use and safety of ibrutinib. METHODS: A cohort study including all patients initiating ibrutinib between 21 November 2014 and 21 November 2018, and followed for 1 year was conducted. Patient characteristics, ibrutinib use and adverse drug reactions (ADRs) were collected from medical records. Kaplan-Meier analysis estimated the probability of developing ibrutinib-associated serious ADRs (SADRs) with a 95% confidence interval (CI). A Cox proportional hazards model was used to investigate factors associated with SADR occurrence. RESULTS: In total, 102 patients were included in the study. The median age was 70.3 years (interquartile range 64.7-75.6), the male/female gender ratio was 2.9. Almost half the patients (47.1%) were prescribed ibrutinib for chronic lymphocytic leukaemia (CLL). Forty-three patients (42.1%) permanently discontinued ibrutinib in the first year, mostly for progression (51.2%) or ADRs (32.6%). Forty-eight patients (47.1%) experienced at least one ibrutinib-associated SADR. Haematological, infectious and vascular disorders were the most frequent SADRs. The probability of developing ibrutinib-associated SADR was 35.1% (95% CI 26.3-45.7%) at 3 months, 44.8% (35.2%; 55.8%) at 6 months and 54.3% (44.0%; 65.2%) at 12 months. Age ≥80 years (hazard ratio [HR] 2.03; 95% CI 1.02-4.05) and CLL (HR 1.81; 95% CI 1.01-3.25) were significantly associated with a higher risk of SADR occurrence. CONCLUSION: This study found a high cumulative incidence of ibrutinib-associated SADRs within the first year of treatment. In view of the risk of SADR, patients aged ≥80 years or treated for CLL deserve special attention.
引用
- Allouchery M, Tomowiak C, Guidez S, et al. Patterns of use and safety of ibrutinib in real-life practice. Br J Clin Pharmacol. 2020. PMID: 32559327. doi:10.1111/bcp.14440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。